| G1 Therapeutics Added to the Russell 2000® and 3000® Indexes | 07/01 08:00 | globenewswire.com |
| G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty | 06/24 10:00 | seekingalpha.com |
| Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday? | 06/24 09:40 | benzinga.com |
| Why Is G1 Therapeutics (GTHX) Stock Down 56% Today? | 06/24 08:23 | investorplace.com |
| G1 Therapeutics' breast cancer drug fails in late-stage trial | 06/24 07:14 | reuters.com |
| G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC) | 06/24 06:30 | globenewswire.com |
| G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 06/05 07:00 | globenewswire.com |
| Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC) | 05/28 06:30 | globenewswire.com |
| G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting | 05/23 17:06 | globenewswire.com |
| G1 Therapeutics to Participate in TD Cowen's 5th Annual Oncology Innovation Summit | 05/22 10:00 | globenewswire.com |